For the quarter ended March 2025, Techne (TECH) reported revenue of $316.18 million, up 4.2% over the same period last year. EPS came in at $0.56, compared to $0.48 in the year-ago quarter.The reported revenue represents a surprise of +0.30% over the Zacks Consensus Estimate of $315.24 million. With the consensus EPS estimate being $0.51, the EPS surprise was +9.80%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

Bio-Techne (TECH) Q3 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants David Clair - Investor RelationsKim Kelderman - CEO, President & DirectorJim Hippel - EVP & CFOPuneet Souda - Senior MDDaniel Markowitz - Vice PresidentDan Arias - Managing DirectorThomas DeBourcy - PrincipalPatrick Donnelly - Managing Director Conference Call Participants Dan Leonard - Managing Director & Research AnalystMatt Larew - Research Analyst - HealthcareSung Ji Nam - Managing Director, Senior Equity Research Anal ...

Bio-Techne (TECH) Q3 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Good morning, and welcome to Bio Techne Earnings Conference Call for the Third Quarter of Fiscal Year twenty twenty five. At this time, all participants have been placed in listen only mode, and the call will be opened for questions following the management's prepared remarks. During our Q and A session, please limit yourself to one question and a follow-up. I would now like to turn the call over to David Claire, Bio Vice President, I ...

Group 1 - Bio-Techne Corporation (TECH) is experiencing significant attention from investors due to high implied volatility in its options market, particularly the Jul 18, 2025 $80 Call option [1] - Implied volatility indicates market expectations for future stock movement, suggesting potential upcoming events that could lead to substantial price changes [2] - Currently, Bio-Techne holds a Zacks Rank 4 (Sell) in the Medical - Biomedical and Genetics industry, with no analysts increasing earnings estimates for the current quarter and one analyst revising estimates downward, resulting in a consensus estimate decrease from 52 cents to 51 cents per share [3] Group 2 - The high implied volatility surrounding Bio-Techne may indicate a developing trading opportunity, as options traders often seek to sell premium on such options to capture decay, hoping the stock does not move as much as anticipated by expiration [4]

Techne (TECH) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.48 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 9.80%. A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.38 per share when it actually produced earnings of $0.42, delivering a surprise of 10.53%. There a ...

Exhibit 99.1 BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS Minneapolis/May 7, 2025/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). Adjusted diluted EPS, adjusted net earnings, adjusted gross margin, adjusted operating income, adjusted tax rate, organic revenue, ...

Summary⚈ Congresswoman April McClain Delaney bought Bio-Techne stock twice in April 2025.⚈ The stock has dropped nearly 30% year-to-date and remains unprofitable post-purchase.⚈ Delaney’s committee roles suggest potential informational advantages in biotech-related decisions.Finbold’s congressional trading radar has recently picked up a suspicious stock bet made by Maryland congresswoman April McClain Delaney involving a low-profile biotech stock. The representative purchased Bio-Techne Corp stock (NASDAQ: ...

SCOTTSDALE, Ariz., April 30, 2025 /PRNewswire/ -- Cyber Enviro-Tech, Inc. (OTCQB: CETI) announced today that it is conducting critical testing of its advanced water purification technology for the oil and gas industry. If successful, the results could lead to contracts potentially valued at over $100 million annually, as referenced in the Company's April 17, 2025 press release.Produced water — a byproduct of oil and gas extraction — typically contains high concentrations of salts, hydrocarbons, heavy metals ...

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to report its third-quarter fiscal 2025 results on May 7, with positive earnings and revenue growth anticipated based on recent performance and market trends [1][2]. Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Bio-Techne's revenues is $315.2 million, reflecting a 3.9% increase from the previous year [2]. - The consensus estimate for EPS is projected at 51 cents, indicating a 6.3% year-over-year improvement [2]. - Recent estimates for EPS have decreased by 1.9% over the past 30 days [2]. Group 2: Segment Performance Insights - The Protein Sciences segment is expected to benefit from its protein analysis portfolio and GMP protein business, with revenues estimated at $224.7 million, up 4.7% from the prior year [3][5]. - The Diagnostics and Spatial Biology segment is anticipated to show solid growth, particularly in the spatial biology vertical, with revenues estimated at $92.5 million, a 5.7% increase from the previous year [6][9]. Group 3: Recent Developments and Innovations - Bio-Techne launched its Simple Western platform called Leo, which allows for high-throughput analysis of samples [4]. - The company expanded its geographic reach through new distribution agreements in Turkey and Azerbaijan, which may positively impact revenue [4]. - The Precision Diagnostic Tools business is experiencing growth, with a unique portfolio that continues to gain market share [7]. Group 4: Collaborations and Product Launches - Bio-Techne's Asuragen brand collaborated with Oxford Nanopore Technologies to launch a new genetic panel, which is expected to enhance business performance [9]. - The company also expanded its menu of RNAscope in situ hybridization probes to support spatial biology research and next-generation therapeutics [8].

Core Insights - Bio-Techne Corporation has launched an Early Access Program for a new assay that enables high-resolution spatial visualization of protein interactions within complex tissues, enhancing the understanding of molecular signaling in disease processes [1][2] Group 1: New Assay Development - The new assay is based on Advanced Cell Diagnostics RNAscope™ technology and allows for in situ detection of protein proximity, providing a spatial solution for exploring functional interactions between proteins [1][2] - This technology addresses limitations of conventional methods that often lose spatial fidelity and do not provide localization data, thus offering a clear visual signal at subcellular resolution [2] Group 2: Research Applications - The assay is particularly valuable for research areas where context is crucial, such as immune checkpoint dynamics, bispecific antibodies, and protein interactions at synaptic junctions [2] - Proof-of-concept data and case studies will be presented at the 2025 American Association for Cancer Research (AACR) annual meeting, showcasing the assay's capabilities [3] Group 3: Company Overview - Bio-Techne Corporation is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [4]